Moderna
Trade Moderna 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About MRNA
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics.
MRNA Key Statistics
Stock Snapshot
With a market cap of 87.19B, Moderna(MRNA) trades at $213.30. The stock has a price-to-earnings ratio of -31.49.
On 2026-11-16, Moderna(MRNA) stock traded between a low of $212.50 and a high of $222.96. Shares are currently priced at $213.30, which is +0.4% above the low and -4.3% below the high.
Moderna(MRNA) shares are trading with a volume of 7.02M, against a daily average of 10.73M.
During the past year, Moderna(MRNA) stock moved between $22.28 at its lowest and $280.80 at its peak.
During the past year, Moderna(MRNA) stock moved between $22.28 at its lowest and $280.80 at its peak.
MRNA News
An announcement from Moderna ( (MRNA) ) is now available. On November 9, 2026, Moderna entered into an amendment to its credit agreement with Ares Capital Corp...
The market has been wildly excited about Moderna (MRNA -3.63%) this year, as it has soared more than 600% since January. The stock has been red hot on news that...
Investing Moderna Is Up Over 600% This Year. Here’s What Jim Cramer Learned in His Exclusive By Chris Lange 𝕏 f ⧉ Quick Read Moderna (MRNA) soared from $63 to a...
Analyst ratings
59%
of 27 ratingsMore MRNA News
Investors are weighing high-growth pharmaceutical specialists against established platform companies. Choosing between Axsome Therapeutics (AXSM -1.86%) and Mod...
Moderna ( (MRNA) ) just unveiled an update. On Nov. 13, 2026, Moderna entered a transitional services and retirement agreement with Chief Legal Officer Shannon...
Moderna (NasdaqGS:MRNA) reported peer reviewed real world data showing its mNEXSPIKE COVID 19 vaccine reduced medically attended COVID 19 in adults aged 65+. T...
In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Hold rating on Moderna, with a price target of $260.00. Alec Strana...
Moderna (MRNA) announced an update on their ongoing clinical study. Study Overview: Moderna’s Phase 3b/4 study, titled A Phase 3b/4 Study to Assess the Immunog...
Moderna (MRNA Quick QuoteMRNA - Free Report) outlined its next phase of growth at its 2026 Analyst Day, highlighting oncology as a key long-term growth op...
BioNTech May Be the Next Moderna. Even if it Isn’t, the Stock Is a Buy. BioNTech has multiple catalysts that could generate a rally of 35% for the stock....
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.